Budesonide Therapy for Colitis

Induction Therapy and Initial Dosing

The American Gastroenterological Association recommends budesonide as the first-line treatment for microscopic colitis, with a standard induction dose of 9mg daily for 8 weeks 1, 2
For mild to moderate ileocecal Crohn's disease, budesonide 9mg once daily for 8 weeks is recommended as first-line therapy, according to the European Crohn’s and Colitis Organisation 3

After achieving remission, budesonide should be tapered over 1-2 weeks rather than abruptly discontinued, as recommended by the European Society of Gastrointestinal Endoscopy 3

For patients with microscopic colitis who experience symptom recurrence after induction therapy, maintenance therapy with budesonide is strongly recommended by the American Gastroenterological Association 1, 4
Maintenance dosing typically starts at 6mg daily but should be tapered to the lowest effective dose in clinical practice, as suggested by the American Gastroenterological Association 1

Patients should be evaluated for symptomatic response to budesonide between 4-8 weeks to determine need for therapy modification, according to the European Crohn’s and Colitis Organisation 5
Although budesonide has low systemic bioavailability, prolonged use may predispose to bone loss, and osteoporosis prevention and screening should be considered in patients requiring long-term maintenance therapy, as recommended by the American Gastroenterological Association 1, 4

Budesonide should not be used for long-term maintenance therapy beyond 6-12 months as prolonged use is associated with significant adverse effects, according to the European Society of Gastrointestinal Endoscopy 5
For Crohn's disease affecting the proximal colon, ileal-release budesonide is beneficial, but there is no evidence of benefit for more distal colonic inflammation, as stated by the European Crohn’s and Colitis Organisation 3
In patients with more severe disease, budesonide is inferior to prednisolone and may not be appropriate, according to the European Crohn’s and Colitis Organisation 3

The American Gastroenterological Association recommends budesonide as the first-line treatment for lymphocytic colitis with a standard induction dose of 9mg daily for 6-8 weeks 6

For patients on maintenance therapy with 3mg daily, a tapering schedule of 3mg every other day for 1 week is recommended 6

The American Gastroenterological Association strongly recommends maintenance therapy with budesonide for patients with recurrence of symptoms following discontinuation of induction therapy 6
Maintenance dosing typically starts at 6mg daily but should be tapered to the lowest effective dose, such as 3mg daily, in clinical practice 6
A lower maintenance dose of budesonide, such as 3mg daily alternating with 6mg daily, over 12 months has shown similar efficacy in maintaining clinical response 6
Cessation of maintenance therapy can be considered after 6 to 12 months 6

Prolonged use of budesonide may predispose to bone loss, and osteoporosis prevention and screening should be considered in patients requiring maintenance therapy beyond 6 months 6